Lite Strategy, Inc.

Stage 2 · Advancing · week 2

As of Oct 22, 2026, Lite Strategy is in Stage 2, the uptrend phase, now in week 2 (since Oct 14, 2026). It closed at $1.19, 47.3% below its 52-week high and above its 200-day average, which is falling.

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. More about the company

$1.19

-4.81% today

$36.2M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is LITS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 23w

S4 37w

S4 26w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 11w → S2 12w → S3 4w → S4 23w → S1 9w → S4 37w → S1 4w → S2 10w → S3 5w → S4 26w → S1 3w → S4 13w → S1 7w → S2 1w current

Total tracked: 165 weeks across 14 stage runs.

LITS among Biotechnology314th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…314	LITSLite Strategy, Inc.	Stage 2 · wk 2	28	+0.8%

vs 52W High

-47.3%

$0.74 lo$2.26 hi

47.3% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 2

1w13w26w

Week 2, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

8.0%

200 DMA: $1.10 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.29x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↗

Short-term trend rising gently

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+0.8%

+20.2%

+0.8%

YTD

-22.7%

-39.0%

Scan Membership

Breakout Watch

Latest: 2023-11-06

7 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 2 · Vol 0.29x

2026-10-21S2

Wk 2 · Vol 0.26x

2026-10-20S2

Wk 1 · Vol 0.39x

2026-10-19S2

Wk 1 · Vol 0.33x

2026-10-16S2

Wk 1 · Vol 0.20x

2026-10-15S2

Wk 1 · Vol 0.56x

2026-10-14S21→2

Wk 1 · Vol 0.49x

2026-10-13S1

Wk 7 · Vol 0.53x

2026-10-12S1

Wk 7 · Vol 0.49x

2026-10-09S1

Wk 7 · Vol 0.99x

2026-10-08S1

Wk 7 · Vol 1.85x

2026-10-07S1

Wk 6 · Vol 1.52x

Moving averages & range

50 DMA

$1.14

200 DMA

$1.10

52W High

$2.26

52W Low

$0.74

5D Low

$1.15

Resistance levels (recent highs)

20d High

$1.44

60d High

$1.44

120d High

$1.44

250d High

$2.26

Next resistance

+21.0%

to 20d High

ROE

-243.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.9

Lite Strategy: quick answers

What stage is Lite Strategy in?

As of Oct 22, 2026, Lite Strategy (LITS) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 14, 2026 and is in week 2. What the four stages mean

Is Lite Strategy in an uptrend?

Yes. Lite Strategy is in a Stage 2 uptrend. It trades 8.0% above its 200-day average, which is falling.

How far is Lite Strategy from its 52-week high?

Lite Strategy closed at $1.19 on Oct 22, 2026, 47.3% below its 52-week high of $2.26. Its 52-week low is $0.74.

How has Lite Strategy performed over the past year?

As of Oct 22, 2026, Lite Strategy is down 39.0% over the past year and down 22.7% so far in 2026.

Which sector and industry is Lite Strategy in?

Lite Strategy is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.